Michael Thomas Heffernan sold $596k of TRVI
director at Trevi Therapeutics, Inc.. 39,473 shares at an average of $15.09, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +19Trade size$596k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-394456, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +18,421 | $3.04 | $56k | 24,772 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -18,321 | $15.09 | $276k | 6,451 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $15.88 | $1,588 | 6,351 | 26 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +21,052 | $3.33 | $70k | 27,403 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -20,952 | $15.09 | $316k | 6,451 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $15.88 | $1,588 | 6,351 | 26 d ago |
| Sep 15, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -18,421 | $0.00 | $0 | 0 | 26 d ago |
| Sep 15, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -21,052 | $0.00 | $0 | 0 | 26 d ago |
Related signals
Other insiders at Trevi Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | TRVIsell Trevi Therapeutics, Inc. | Jennifer L Good President & CEO | $35k 5,263 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.